TRANSITION TO A COMMERCIAL AND PROFITABLE PHARMACEUTICAL COMPANY CONTINUES. Presenting at Småbolagsdagen June 10, 2013
|
|
- Andrea Blake
- 8 years ago
- Views:
Transcription
1 TRANSITION TO A COMMERCIAL AND PROFITABLE PHARMACEUTICAL COMPANY CONTINUES Presenting at Småbolagsdagen June 10, 2013
2 LEGAL DISCLAIMER This presentation, which is personal to the recipient, has been prepared and produced by Orexo AB (publ) ( Orexo ) solely for the benefit of investment analysis and may not be used for any purpose other than assessment of investments concerning Orexo. Unless otherwise stated, Orexo is the source for all data contained in this presentation. Such data is provided as at the date of this presentation and is subject to change without notice. This presentation is strictly confidential and is being furnished to you solely for your information. It may not be reproduced, redistributed, passed on or published, in whole or in part, to any other person for any other purpose. This presentation does not constitute or form part of, and should not be construed as, an offer or invitation for the sale of or the subscription of, or a solicitation of any offer to buy or subscribe for, any securities, nor shall it or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any offer, contract, commitment or investment decision relating thereto, nor does it constitute a recommendation regarding the securities of Orexo. Neither this presentation nor any copy of it may be taken, transmitted into or distributed in the United States, the United Kingdom, Canada, Australia or Japan except by or on the express instructions of Orexo. The distribution of this presentation in other jurisdictions may also be restricted by law and persons into whose possession this presentation comes should inform themselves about and observe any such restrictions. The shares of Orexo have not been registered under the U.S. Securities Act of 1933, as amended (the Securities Act"), and may not be offered or sold in the United States (as such term is defined in Regulation S under the Securities Act) except pursuant to an exemption from, or a transaction not subject to, the registration requirements of the Securities Act or unless registered under the Securities Act. This presentation is directed only at persons who: (i) are outside the United Kingdom; or (ii) have professional experience in matters relating to investments falling within article 19(5) of the Financial Services and Markets Act 2000 (financial promotion) order 2005 ( the order ); or (iii) are persons to whom it can otherwise lawfully be distributed (all such persons together being referred to as relevant persons ). This presentation must not be acted on, or relied on by, persons who are not relevant persons. The information in this presentation has not been independently verified. No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy or completeness of the information or opinions contained herein. None of Orexo, any of its shareholders, or any of their respective subsidiary undertakings or affiliates or any of such person s directors, officers or employees, advisers or other representatives, accepts any liability whatsoever (whether in negligence or otherwise) arising, directly or indirectly, from the use of this presentation or otherwise arising in connection therewith. This presentation includes forward-looking statements. These forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance, achievements or industry results to be materially different from those expressed or implied by these forward-looking statements. Forward-looking statements speak only as of the date of this presentation and Orexo expressly disclaim any obligation or undertaking to release any update of, or revisions to, any forward-looking statements in this presentation as a result of any change in our expectations or any change in events, conditions or circumstances on which these forward-looking statements are based. This presentation is not a prospectus in accordance with the Swedish Financial Instruments Trading Act (Sw. lagen (1991:981) om handel med finansiella instrument) or any other Swedish laws or regulations. Neither the Swedish Financial Supervisory Authority (Sw. Finansinspektionen) nor any other Swedish regulatory body has examined, approved or registered this presentation. Page 2
3 OREXO COMPANY OVERVIEW PROVEN DEVELOPMENT TRACK RECORD BASED ON FORMULATION STRATEGY US Product. Proprietary US commercial product in 2013 FORMULATION TECHNOLOGY (Sublingual Delivery) Zubsolv for opioid dependence Platform & Pipeline. Sublingual formulation technologies driving products and pipeline PROPRIETARY PRODUCTS PIPELINE Zubsolv: Opioid dependence OX51: Procedure-induced pain OX27: BTCP Revenues. Portfolio of revenue generating US/EU partnered products Manufacturing. In-house GMP facility approved for controlled substances PARTNERED PRODUCTS PIPELINE Abstral: BTCP (Kyowa ex US, Galena BioPharma US) Edluar : Insomnia (Meda) OX-CLI: Astra Zeneca 1 OX-MPI: Boehringer Ingelheim 1 1) Not based on drug delivery technology Page 3
4 THE START OF A NEW COMMERCIAL CHAPTER IN THE OREXO EVOLUTION 2013 has started in a fast pace to continue focusing the business New CEO appointed in February Agreement with Astra Zeneca on OX-CLI Agreement with Galena Biopharma on Abstral, worth $15M (SEK 97,5M) in one time payments and additional royalty expected Successful Zubsolv launch, the primary objective of 2013 Target date for approval of Zubsolv set for early July, 2013 Significant clinical programs initiated to gain differentiation Establish commercial infrastructure in the US Launch anticipated in September 2013 Other projects and products to continue strengthen the Orexo base Abstral approval in Japan OX51 results from a dose-finding phase II study expected Edluar launch in Europe Page 4
5 ZUBSOLV OREXO LEAD VALUE DRIVER
6 SIGNIFICANT MARKET FOR OPIOID DEPENDENCE 44% 11% ~40% Established ~35-45% Pharma Focus Chronic Pain 1 N=109 MM Rx Opioids for Chronic Pain 2 N=~48 MM Develop Dependence 3 N=5 MM Diagnosed Dependent 4,5 N=2 MM Treated 6 N= K Increased ambition to control opioid use but lack of good alternatives Opioids are highly addictive with 11% developing dependence Majority of opioid users are unaware of own dependence and/or believe they can wean off by themselves Lack of prescribing physicians and even if referred few dependents receive treatment ~50% Suboxone 7 ~3M patients have been treated with Suboxone N=400 K Zubsolv market-entry focus Source: Trinity Market Reserach, October ) Committee on Advancing Pain, Research and Education (N and %) 2) Clark, J.D., J Pain Symptom Manage (2002) (%) 3) NSDUH (N) 4) Peer, K, Drug and Alcohol Dependence (2012) (%) 5) Healthcare for Communities Survey (%) 6) NSDUH; Trinity experienced based on Rx data (N); Decision Resources (%) 7) Presentation at SAMHSA buprenorphine meeting (N) Page 6
7 CHANGES IN US LEGISLATION WILL DRIVE DEMAND FOR ZUBSOLV IN THE US The Obama administration issued a final rule on Wednesday defining essential health benefits that must be offered by most health insurance plans next year... The federal rule requires insurers to cover treatment of mental illnesses, behavioral disorders, drug addiction. [New York Times, Feb 20 th, 2013] Under healthcare reform, millions of people will become eligible for insurance coverage starting in January. The number of people seeking addiction treatment could double [Associated Press, April 16 th, 2013] "There is no illness currently being treated that will be more affected by the Affordable Care Act than addiction," Tom McLellan, CEO of the nonprofit Treatment Research Institute, [Associated Press, April 16 th, 2013] Page 7
8 SUBOXONE IS A US BLOCKBUSTER THAT CONTINUES TO DEMONSTRATE DOUBLE-DIGIT GROWTH Suboxone Tablet Launched 2003 US SALES (IN MILLIONS OF USD) Film approved in August % +38% Marketed by Reckitt Benckiser Sales of $1.5 billion in 2012 Sales growth of 21% in Q1-Q ,4% TRx growth Growth drivers: Growing number of sufferers Increasing proportion seeking therapy Price increases Sources: IMS, RB Annual report, Credit Suisse Reports on RB Page 8
9 ZUBSOLV IS WELL POSITIONED TO REPEAT SUCCESSFUL INTRODUCTION OF SUBOXONE FILM BUP/NLX market evolution Suboxone Tablet Suboxone Film Zubsolv First in class buprenorphinenaloxone combination product Replacing stigmatized abuse clinics enabled broader population to be treated for opioid dependency Improved formulation, dissolved faster and improved taste masking Further improvement of dissolve time, taste masking and mouth feel over Tablet Preferred by 9 out of 10 participants in an acceptability study compared to the Suboxone Film Page 9
10 STUDY COMPARING WITH SUBOXONE FILM SHOWS 89% WOULD CHOOSE ZUBSOLV DRIVEN BY TASTE, ADMINISTRATION AND AFTERTASTE OVERALL PREFERENCE (WHICH TREATMENT WOULD YOU CHOOSE?) Suboxone Film 89% Zubsolv TM Taste (WHICH TASTE DO YOU PREFER?) Suboxone Film Ease of administration (WHICH TREATMENT IS MOST EASY TO ADMINISTER?) Suboxone Film Unpleasant aftertaste (SHARE OF PARTICIPANTS WITH NO UNPLEASANT AFTER TASTE?) 96% 89% Zubsolv TM Zubsolv TM 57% 7% p < p < Zubsolv (OX219) Suboxone Page 10
11 FOCUS OF ZUBSOLV IS TO BECOME THE PREFERRED CHOICE FOR ALL PATIENTS Payer At least equal payer coverage for Zubsolv Price competitive Prescriber Aware of Zubsolv superior product features and make is available for patients FDA Comparable label and REMS with Suboxone Zubsolv the patients choice Patients Improved support program and equal financial support to Suboxone Page 11
12 ABSTRAL TREATMENT OF BREAKTHROUGH CANCER PAIN
13 ABSTRAL FOR BREAKTHROUGH CANCER PAIN (BTCP) FAST-ACTING SUBLINGUAL TABLET FORMULATION OF FENTANYL CITRATE FAST-ACTING Sublingual TABLET formulation of fentanyl citrate Launched in EU in 2008 Launched in US in 2011 Orexo acquired back rights to the US in June 2012 Approval and launch anticipated in Japan during 2013 Abstral - the only fast dissolving (in less than a min) sublingual tablets in the category Patients require o o o Fast onset Easy administration Good taste experience Breakthrough pain episode Basal Opioid Page 13
14 RECONFIGURATION OF ABSTRAL RIGHTS GENERATE MORE THAN MSEK 700 IN FIXED PAYMENTS European rights sold to Kyowa Kirin for MSEK 610 US rights sold to Galena Biopharma Inc for MSEK 98 Double digit royalty remain in all geographies except Japan EU for sales exceeding MEUR 42.5 Double digit royalty in ROW and Europe over MEUR 42.5 Fixed payments and milestone Single digit royalty in Japan and approval milestone MUSD 10 upfront and MUSD 5 within first 12 months Double digit royalty 1) Will be reported as revenue in equal monthly amounts over the 12-month period subsequent to when received. 2) Exchange rate of 1.60 USD per GBP. Page 14
15 FINANCIALS
16 NET REVENUES JANUARY-MARCH 2013 MSEK Q Q FY 2012 Abstral -royalties Abstral - milestone payment Edluar -royalties ProStrakan AB joint venture 50 % Kibion Total revenues from launched products Partner-financed R&D-costs Licensing revenue for development projects Other Total Page 16
17 P&L IN SUMMARY Q1 Q1 FY MSEK Net revenues Cost of goods sold Gross Profit Selling expenses Administrative expenses Research & development expenses Other operating income & expenses Operating Costs -102, EBIT Net financial items EBT Tax Net profit/loss EBITDA Page 17
18 FINANCIAL POSITION Cash flow Q1 Q1 FY MSEK Cash flow from operating activities Investment activities -5, Financing activities Cash flow Liquid funds Financing activities 2012 FY include shares bought back amounting to MSEK 53 Abstral royalty (EU) paid in one yearly payment (June) Limited CAPEX in Zubsolv production equipment Page 18
19 SUMMARY: OREXO IS AT A TURNING POINT Preparing the most important launch in the history of Orexo Zubsolv. Entering a commercial space with outstanding macro development Continuous market growth of $1,5 billion market High unmet need >5 million patients Political changes driving growth, addiction treatment an essential health benefit Best-in-class product close to approval with launch expected in September 9 out of 10 would choose Zubsolv compared to market leader Orexo is well positioned to make this happen Commercial team in Sweden and US with strong track-record Financial strength Strategic flexibility to find solution generating most share holder value Page 19
20 Q & A Page 20
21 TRANSITION TO A COMMERCIAL AND PROFITABLE PHARMACEUTICAL COMPANY CONTINUES
OREXO AB SPECIALTY PHARMA FOCUSING ON OPIOID DEPENDENCE AND PAIN TREATMENT NORDIC LIFE SCIENCE CONFERENCE
OREXO AB SPECIALTY PHARMA FOCUSING ON OPIOID DEPENDENCE AND PAIN TREATMENT NORDIC LIFE SCIENCE CONFERENCE NASDAQ STOCKHOLM: ORX US OTC MARKET: ORXOY (ADR) APRIL 27 TH, 2015 LEGAL DISCLAIMER This presentation,
More informationInterim report January-September 2015
Interim report January-September 2015 Unless otherwise stated in this report, all data refers to the Group. Figures in parentheses relate to the corresponding period in 2014. Zubsolv growth driven by patient
More informationHoist Finance announces its intention to launch an initial public offering and listing on Nasdaq Stockholm
Press release Stockholm 26 February 2015 Hoist Finance announces its intention to launch an initial public offering and listing on Nasdaq Stockholm Hoist Finance AB (publ) ( Hoist Finance or the Company
More informationHow To Sell A Share In Amsterdam Molecular Therapy
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION INTO OR IN THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN 6 June 2007 Amsterdam Molecular Therapeutics announces launch of Initial Public Offering (IPO) on Euronext
More informationUpdate following the publication of the Bank of England Stress Test. 16 December 2014
Update following the publication of the Bank of England Stress Test 16 December 2014 Background Top 8 Banks Resilience Stress Tested by PRA following FPC recommendation in March 2013 Guidance for stress
More informationAdif - Alta Velocidad
Adif - Alta Velocidad Investor Presentation January 2015 Adif - Alta Velocidad Receipt of this presentation implies your agreement with the restrictions outlined below. NOTHING IN THIS PRESENTATION CONSTITUTES
More informationFONDUL PROPRIETATEA S.A.
To: Bucharest Stock Exchange Financial Supervisory Authority Current report according to Article 99 of the Code of the Bucharest Stock Exchange, Title II, Issuers and Financial Instruments. Events to be
More informationFull year report January-December 2015
Full year report January-December 2015 Unless otherwise stated in this report, all data refers to the Group. Figures in parentheses relate to the corresponding period in 2014. 2015 a year of investments
More informationDisclosure. This presentation contains forward-looking statements.
Disclosure This presentation contains forward-looking statements. These forward-looking statements are based on management's current expectations and assumptions as of the date of this presentation, and
More information2008 Interim Results September 2008
2008 Interim Results September 2008 Kenneth Alexander Chief Executive Gerard Cassels Finance Director Disclaimer This presentation is being made only in the United Kingdom and is directed only at (i) persons
More informationQSC AG. Company Presentation. Results Q1 2014 Cologne, May 12, 2014
QSC AG Company Presentation Results Q1 2014 Cologne, May 12, 2014 AGENDA 1. Highlights Q1 2014 2. Financial Results Q1 2014 3. Outlook 2014 4. Questions & Answers 2 2014 STARTED AS EXPECTED Two-track development
More informationLondon Stock Exchange Symbol: PLUS
London Stock Exchange Symbol: PLUS 1 Disclaimer The Presentation does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe
More informationPresentation to Dockwise. 24 April 2012
Presentation to Dockwise 24 April 2012 Disclaimer This presentation has been prepared by Fairstar Heavy Transport NV ( FHT or the company ). This presentation is for information purposes only. This presentation
More informationSBERBANK GROUP S IFRS RESULTS. March 2015
SBERBANK GROUP S IFRS RESULTS 2014 March 2015 SUMMARY OF PERFORMANCE FOR 2014 STATEMENT OF PROFIT OR LOSS Net profit reached RUB 290.3bn (or RUB 13.45 per ordinary share), compared to RUB 362.0bn (or RUB
More informationSberbank Group s IFRS Results for 6 Months 2013. August 2013
Sberbank Group s IFRS Results for 6 Months 2013 August 2013 Summary of 6 Months 2013 performance: Income Statement Net profit reached RUB 174.5 bn (or RUB 7.95 per ordinary share), a 0.5% decrease on RUB
More informationINTENTION TO FLOAT ( ITF ) Press release, 14/01/2014
INTENTION TO FLOAT ( ITF ) Press release, 14/01/2014 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN This announcement is not
More informationRUNNINGBALL ACQUISITION INVESTOR PRESENTATION
RUNNINGBALL ACQUISITION INVESTOR PRESENTATION TRANSACTION HIGHLIGHTS Proposed acquisition of RunningBall group, a leading provider of real-time sports data to the online sports betting sector Consideration
More informationTelio & NextGenTel. NextGenTel Holding ASA. Q1 2015 Presentation. Eirik Lunde, CEO. Felix Konferansesenter Oslo 7 May 2015
Telio & NextGenTel NextGenTel Holding ASA Q1 215 Presentation Eirik Lunde, CEO Felix Konferansesenter Oslo 7 May 215 This is NextGenTel Group Background Telio Pioneer in the Norwegian VoIP market rapid
More informationCapio intends to be listed on the Nasdaq Stockholm Stock Exchange
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, TO U.S. NEWS WIRE SERVICES OR PUBLICATION IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, NEW ZEALAND, SOUTH AFRICA, HONG KONG, SINGAPORE
More informationX5 Retail Group Capital Markets Day
X5 Retail Group Capital Markets Day Presentation for Investors Janusz Lella 11 th October, 2013 General Director of Perekrestok 11 October 2013 Disclaimer This presentation does not constitute or form
More informationQSC AG. Company Presentation. Results Q3 2013 Cologne, November 11, 2013
QSC AG Company Presentation Results Q3 2013 Cologne, November 11, 2013 AGENDA 1. Highlights Q3 2013 2. Financial Results Q3 2013 / Outlook 3. Questions & Answers 2 SOLID DEVELOPMENT IN Q3 2013 QSC is well
More informationNICKEL MOUNTAIN GROUP AB
Company presentation NICKEL MOUNTAIN GROUP AB «Building a high growth, high return debt management services company» 16 October 2015 NOT FOR REPRODUCTION OR DISTRIBUTION. THE INFORMATION CONTAINED HEREIN
More informationQSC AG. Company Presentation. Results Q1 2013 Cologne, May 13, 2013
QSC AG Company Presentation Results Q1 2013 Cologne, May 13, 2013 AGENDA 1. Highlights Q1 2013 2. Financial Results Q1 2013 3. Outlook 2013 4. Questions & Answers 2 GOOD START TO 2013 Favorable revenue
More informationGeoff Miller CEO. GLI Finance. February 2014
Geoff Miller CEO GLI Finance February 2014 1 Disclaimer IMPORTANT NOTICE These presentation materials (the "Presentation Materials") are being solely issued to and directed at persons who are qualified
More informationQSC AG. Company Presentation. Preliminary Results 2013 / Outlook for 2014 Cologne, February 26, 2014
QSC AG Company Presentation Preliminary Results 2013 / Outlook for 2014 Cologne, February 26, 2014 AGENDA 1. Strategic Development 2013 2. Financial Development 2013 3. Outlook for 2014 4. Questions &
More informationTetragon Financial Group Limited ( TFG )
Tetragon Financial Group Limited ( TFG ) 12 August 2014 THE INFORMATION CONTAINED HEREIN DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO PURCHASE ANY SECURITY OF TFG. THIS INFORMATION
More informationFocus on fleet customers SAF-HOLLAND Annual Financial Statements 2013
Focus on fleet customers SAF-HOLLAND Annual Financial Statements 213 Detlef Borghardt, CEO Wilfried Trepels, CFO March 13, 214 Agenda 1 Financials 3 2 Appendix 21 2 Executive Summary 1 2 3 Group sales
More information2014 FULL YEAR RESULTS
2014 FULL YEAR RESULTS -3% -8% Financial and Operational Highlights Operational Revenue mntl (1) Ancillary Revenue/Pax Load Factor 29% 16% 13% 22% TRY mn 2.38 4,7 TRY mn 3.08 1,7 TRYm n 569,3 TRYm n 661,9
More informationIPH LIMITED IPH LAUNCHES A$60 MILLION UNDERWRITTEN INSTITUTIONAL PLACEMENT AND SHARE PURCHASE PLAN
ASX Announcement Tuesday, 24 November 2015 Company Announcements Office ASX Limited Level 4, 20 Bridge Street Sydney, NSW 2000 IPH LIMITED IPH LAUNCHES A$60 MILLION UNDERWRITTEN INSTITUTIONAL PLACEMENT
More informationSAF-HOLLAND Annual Financial Statements 2012. Detlef Borghardt, CEO Wilfried Trepels, CFO. March 14, 2013
SAF-HOLLAND Annual Financial Statements 212 Detlef Borghardt, CEO Wilfried Trepels, CFO March 14, 213 Executive Summary business volume successfully expanded in 212 1 Group sales increased yoy by 3.4%
More informationVOLEX INTERIM RESULTS TO OCTOBER 5 2014. Christoph Eisenhardt, CEO Nick Parker, CFO November 2014
VOLEX INTERIM RESULTS TO OCTOBER 5 2014 Christoph Eisenhardt, CEO Nick Parker, CFO November 2014 Disclaimer This Presentation has been prepared by Volex PLC (the Company ) in connection with the publication
More informationInterim report Second quarter 2015
Interim report Second quarter 2015 Oslo, 20 August 2015 Presenters and agenda Agenda Hans-Petter Mellerud Founder and CEO Highlights for the quarter Financial performance Regional trends Nina Stemshaug
More informationRESULTS FIRST QUARTER 2015
0 April 27, 2015 RESULTS FIRST QUARTER 2015 An integrated energy player focused on exploration and production DISCLAIMER 1 RCA figures except otherwise noted. By attending or reading this presentation,
More informationIntertrust N.V. announces the indicative price range, offer size, start of offer period and publication of prospectus of its planned IPO
This press release and the information contained herein are not for distribution in or into the United States of America (including its territories and possessions, any state of the United States of America
More informationAcquisition of AlliedBarton Security Services. June 30, 2015
Acquisition of AlliedBarton Security Services June 30, 2015 1 Introduction On June 29, Wendel agreed to acquire AlliedBarton Security Services, the second largest security officer services provider in
More informationDVP settlement in NSD
DVP settlement in NSD DVP* settlement as defined by G10 workgroup**: DVP 1: Transfer instructions for both securities and funds are settled on a trade by trade basis, with final transfer of the securities
More informationpressrelease ROCKET INTERNET PRICES IPO AT TOP OF PRICE RANGE MANILA, Philippines, 2 nd October 2014 - Philippine Long Distance Telephone Company ( PLDT ) (PSE:TEL) (NYSE:PHI), the leading telecoms operator
More informationScotiabank Financials Summit September 4, 2014
Scotiabank Financials Summit September 4, 2014 Customers Capital Bank ~7,000 customers, high level of recurring revenue 2 Forward-Looking Statements This presentation contains certain statements that constitute
More informationNOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN
Investor News NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN Bayer plans IPO for Covestro Listing on Frankfurt Stock Exchange intended in Q4 2015
More information2015 Investor Day CFO Presentation. June 25, 2015
The Critical Materials Company 2015 Investor Day CFO Presentation June 25, 2015 Table of Contents Q1 2015 Financial Highlights 4 Currency Translation Effect 5 AMG Q1 2015 At a Glance 6 AMG Critical Materials
More informationAnalyst Roundtable. Cologne, December 12, 2013
QSC AG Analyst Roundtable Cologne, December 12, 2013 AGENDA 1. Operational Update Barbara Stolz CFO 2. Strategic Update Juergen Hermann CEO 3. Presentation of Selected Innovations - QSC-WiFi - QSC-tengo
More informationApril 2016. Bruno Jactel, CEO Erica Boisvert, CFO
April 2016 Bruno Jactel, CEO Erica Boisvert, CFO OUR MISSION TYRATECH Is a life science technology company focused on: pesticide-free products to control insects and parasites 1 ton of pesticide per person/year!
More information2015 FIRST HALF RESULTS CONFERENCE CALL. August 31st, 2015
2015 FIRST HALF RESULTS CONFERENCE CALL August 31st, 2015 DISCLAIMER This presentation has been prepared by Eurotech S.p.A.(or Eurotech ) and has to be read in conjunction with its oral presentation. The
More informationAurora Investment makes a partial public cash offer to the shareholders in Anoto Group for up to 20.0 per cent. of the shares
March 5, 2010 at 8.15 For immediate release THIS PRESS RELEASE IS NOT AND MUST NOT, DIRECTLY OR INDIRECTLY, BE DISTRIBUTED OR MADE PUBLIC IN THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, NEW ZEALAND OR
More informationConference Call. WASHTEC AG H1 2015 Report
Conference Call WASHTEC AG H1 2015 Report. Strongest H1 in WashTec s history Revenues (in m): + 13,2% incl. FX EBIT (in m): more than doubled Net Cash Flow (in m) 160.6 13.8 12.9 139.9 141.9 5.9 7.7 7.3
More informationQSC AG. Company Presentation Results Q3 2009. Cologne, November 9, 2009 9.11.09
QSC AG Company Presentation Results Q3 2009 Cologne, November 9, 2009 1 9.11.09 AGENDA 1. Financial Results Jürgen Hermann, Chief Financial Officer 2. Operational Update & Outlook Dr. Bernd Schlobohm,
More informationTHE DIGITISER OF THE GERMAN MITTELSTAND
Cologne, 9 November 2015 Results Q3 2015 THE DIGITISER OF THE GERMAN MITTELSTAND 1. Strategic Update QSC well on track in Q3 2015 Strong increase in profitability and financial strength (Y-o-Y: EBITDA:
More informationBackground information. Changes in the shareholder structure and balance sheet. Contract with Google prolonged for two years
A cc or # $T ypcap$ 1628 1 0 4 2 Page 1/5 Equity flash Newsflow Telecommunication HOLD (HOLD) Target EUR 4.00 (EUR 4.00) Price (last closing price) : EUR 2.84 Upside : 40 % Est. change 2015e 2016e EPS
More informationH1 2014 IFRS Results. August 2014
H 4 IFRS Results August 4 Important Notice By attending the meeting where the presentation is made, or by reading the presentation slides, you agree to the following limitations and notifications and represent
More informationIntroduction. Anders Runevad, Group President & CEO Marika Fredriksson, Executive VP & CFO
Introduction Anders Runevad, Group President & CEO Marika Fredriksson, Executive VP & CFO Aarhus, 12 June 2014 Disclaimer and cautionary statement This presentation contains forward-looking statements
More informationIT SOLUTIONS MOSCOW EXCHANGE
IT SOLUTIONS MOSCOW EXCHANGE CONTENTS Network connectivity Selection of network solutions 1 Universal DMA scheme 2 ConnectME 3 Co-location 4 Internet connection 5 Global Connectivity 6 DMA interfaces Terminals
More informationEQUITY RAISING ANNOUNCEMENT
EQUITY RAISING ANNOUNCEMENT MARKET RELEASE 21 NOVEMBER 2012 KEY POINTS Entitlement Offer to Raise up to A$80 million o 3 for 10 accelerated non renounceable entitlement offer to raise up to A$80 million
More informationFull Year Report 2005. 26 January 2006
Full Year Report 2005 26 January 2006 Important Notice This Presentation has been produced by TradeDoubler AB (the Company ) and is furnished to you solely for your information. This document contains
More informationMunksjö Oyj A global leader in specialty paper
Munksjö Oyj A global leader in specialty paper SEB Enskilda Nordic Seminar, Copenhagen, 8 January 2014 Jan Åström, President and CEO Important notice This document may not be distributed in or into Australia,
More informationQuality Affordable Healthcare Products. Perrigo Company to Acquire Elan to Create Premier Global Healthcare Company July 31, 2013
Perrigo Company to Acquire Elan to Create Premier Global Healthcare Company July 31, 2013 Important Information For Investors And Shareholders This announcement does not constitute an offer to sell, or
More informationNYSE MKT: AXN. Pain Management, Psychiatric Treatment, Addiction Treatment, Weight Loss Treatment Narcotic Pharmaceuticals
Aoxing Pharmaceutical Company, Inc. NYSE MKT: AXN Pain Management, Psychiatric Treatment, Addiction Treatment, Weight Loss Treatment Narcotic Pharmaceuticals State Designated Narcotics Manufacturer Forward
More informationNord Gold N.V. Separation. December 5, 2011. London
Nord Gold N.V. Separation December 5, 2011. London Disclaimer Page 2 NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES OF AMERICA, THE RUSSIAN FEDERATION OR ANY JURISDICTION WHERE TO DO SO WOULD VIOLATE
More informationTetragon Financial Group Limited ( TFG )
Tetragon Financial Group Limited ( TFG ) 29 October, 2012 THE INFORMATION CONTAINED HEREIN DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO PURCHASE ANY SECURITY OF TFG. THIS INFORMATION
More informationRe: Agreement to Commence the Process for the Acquisition of Amlin, a UK Insurance Holding Company by Mitsui Sumitomo Insurance
September 8, 2015 MS&AD Insurance Group Holdings, Inc. Re: Agreement to Commence the Process for the Acquisition of Amlin, a UK Insurance Holding Company by Mitsui Sumitomo Insurance Mitsui Sumitomo Insurance
More informationMERKO EHITUS GROUP Annual General Meeting of Shareholders. 29 April 2015 Nordic Hotel Forum, Tallinn
MERKO EHITUS GROUP Annual General Meeting of Shareholders 29 April 2015 Nordic Hotel Forum, Tallinn Agenda 1. Approval of the annual report of the year 2014 and overview of the results and the prospective
More informationAnnual Financial Results Presentation for year ended 30 June 2014 2 October 2014
Annual Financial Results Presentation for year ended 30 June 2014 2 October 2014 Disclaimer The information contained in this presentation ( Presentation ) has been prepared by Firestone Diamonds plc (the
More informationThe Board of Directors of Elektrobit Corporation has approved a plan for partial demerger. CEO Jukka Harju February 19, 2015
The Board of Directors of Elektrobit Corporation has approved a plan for partial demerger CEO Jukka Harju February 19, 2015 BACKGROUND AND RATIONALE Background for the partial demerger Elektrobit Corporation
More information2014 FIRST QUARTER RESULTS CONFERENCE CALL. May 15th, 2014
2014 FIRST QUARTER RESULTS CONFERENCE CALL May 15th, 2014 DISCLAIMER This presentation has been prepared by Eurotech S.p.A.(or Eurotech ) and has to be read in conjunction with its oral presentation. The
More informationQSC AG. Company Presentation. Results Q2 2014 Cologne, August 11, 2014
QSC AG Company Presentation Results Q2 2014 Cologne, August 11, 2014 AGENDA 1. Operating development Q2 2014 2. Financial development Q2 2014 3. Outlook for 2014 4. Questions & Answers 2 DISAPPOINTING
More informationAdif - Alta Velocidad
Adif - Alta Velocidad Investor Presentation May 2014 Adif - Alta Velocidad Receipt of this presentation implies your agreement with the restrictions outlined below. NOTHING IN THIS PRESENTATION CONSTITUTES
More informationQ1/2015 Results VTG AG Connecting worlds. Dr. Heiko Fischer, CEO Dr. Kai Kleeberg, CFO May 21, 2015
Q1/2015 Results VTG AG Connecting worlds Dr. Heiko Fischer, CEO Dr. Kai Kleeberg, CFO May 21, 2015 Table of content 1 Discussion of Q1/2015 2 Outlook FY 2015 3 Questions & Answers 4 Financial Calendar
More informationINVESTOR CALL RESULTS OF THE FISCAL YEAR 2014/15
INVESTOR CALL RESULTS OF THE FISCAL AR 2014/15 Mannheim, 13 May 2015 Oliver Windholz CEO Helmut Fischer CFO Disclaimer 2015 PHOENIX Pharmahandel GmbH & Co KG This document has been prepared by PHOENIX
More informationAchmea Investment Management. 26 May 2016 Jacob de Wit Leiden
Achmea Investment Management 26 May 2016 Jacob de Wit Leiden Key messages Strategic choice of Achmea for Retirement Services with Achmea IM as Asset Manager Centralisation of asset management activities
More informationMEDICAL POLICY Treatment of Opioid Dependence
POLICY........ PG-0313 EFFECTIVE......11/11/14 LAST REVIEW... 07/14/15 MEDICAL POLICY Treatment of Opioid Dependence GUIDELINES This policy does not certify benefits or authorization of benefits, which
More informationGlobal Investments Limited. FY2014 Financial Results
Global Investments Limited FY2014 Financial Results DISCLAIMER Information contained in this presentation is intended solely for your personal reference and is strictly confidential. Such information is
More informationA World Leading Addiction Treatment Company with enormous future potential. Jefferies Healthcare Conference 2014
A World Leading Addiction Treatment Company with enormous future potential Jefferies Healthcare Conference 2014 Disclaimer. For the purposes of this disclaimer the "Presentation" shall mean and include
More informationSaft Groupe SA Full year results 2014
Saft Groupe SA Full year results 2014 Paris, February 18 th, 2015 Disclaimer This document contains certain forward-looking statements relating to the business, financial performance and results of the
More informationNot for distribution in the United States, Canada, Australia or Japan
The distribution of this press release, directly or indirectly, in or into the United States, Canada, Australia or Japan is prohibited. This press release (and the information contained herein) does not
More informationING (US) ISSUANCE LLC REGISTRATION DOCUMENT
Dated 15 May 2009 ING (US) ISSUANCE LLC REGISTRATION DOCUMENT Table of Contents Page INTRODUCTION... 1 DOCUMENTS INCORPORATED BY REFERENCE... 3 RISK FACTORS... 4 DESCRIPTION OF ING (US) ISSUANCE LLC....
More informationAccount structure. OTC and onexchange. settlement flows. Settlement
Account structure. OTC and onexchange settlement flows Settlement Nominee securities accounts structure according to the new Clearing Law Required by legislation Always should be opened but could have
More informationNordic Waterproofing announces its initial public offering on Nasdaq Stockholm and prospectus in connection therewith
PRESS RELASE Helsingborg, Sweden, 30 May 2016 Nordic Waterproofing announces its initial public offering on Nasdaq Stockholm and prospectus in connection therewith IN WHICH THE DISTRIBUTION OR RELEASE
More informationConditional Regulatory Clearance of the acquisition of E-Plus
Creating a Leading Digital Telco Conditional Regulatory Clearance of the acquisition of E-Plus July 2014 Disclaimer This document contains statements that constitute forward-looking statements and expectations
More informationQSC AG Company Presentation Results Q1 2011. Cologne, May 9, 2011
QSC AG Company Presentation Results Q1 2011 Cologne, May 9, 2011 1 AGENDA 1. Highlights Q1 2011 2. Financial Results Q1 2011 3. Outlook 2011 4. Questions & Answers 2 MAJOR ACHIEVEMENTS IN 2011 UP TO NOW
More informationN a s d a q : I N S Y
N a s d a q : I N S Y Michael L. Babich, President and Chief Executive Officer Darryl S. Baker, Chief Financial Officer Jeffries Healthcare Conference, June 2014 Safe Harbor Statement This presentation
More informationFinancial Overview. Olivier Dubois. Investor Presentation. President and CFO. Paris, October 17, 2007 - New York, October 19, 2007
Financial Overview Olivier Dubois President and CFO Investor Presentation Paris, October 17, 2007 - New York, October 19, 2007 Current situation 2 Technip financial statements FULL YEAR FIRST SEMESTER
More informationOW BUNKER ANNOUNCES INTENTION TO LAUNCH AN IPO AND TO SEEK A LISTING ON NASDAQ OMX COPENHAGEN
PRESS RELEASE 5 March 2014 NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN This announcement is not a prospectus
More information2015 FULL YEAR RESULTS CONFERENCE CALL. March 14th, 2016
2015 FULL YEAR RESULTS CONFERENCE CALL March 14th, 2016 DISCLAIMER This presentation has been prepared by Eurotech S.p.A.(or Eurotech ) and has to be read in conjunction with its oral presentation. The
More informationRecommended Acquisition of Networkers International plc Presentation to Analysts & Investors
Recommended Acquisition of Networkers International plc Presentation to Analysts & Investors 28 January 2015 Disclaimer THIS PRESENTATION IS NOT AN OFFER OR SOLICITATION OF AN OFFER TO BUY OR SELL SECURITIES.
More informationPorta Communications Plc Holding(s) in Company
16 th December 2013 Porta Communications Plc Holding(s) in Company For filings with the FCA include the annex For filings with issuer exclude the annex TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES i
More informationIntroducing SIR/GVV: the new Belgian REIT status
Introducing SIR/GVV: the new Belgian REIT status July 2014 1 Disclaimer This presentation (the Presentation) has been prepared by members of the working group (the Company) in connection with the adoption
More informationEFG International updates on the financing for the combination with BSI and outlines key proposals relating to its Annual General Meeting
THIS IS A RESTRICTED COMMUNICATION AND YOU MUST NOT FORWARD IT OR ITS CONTENTS TO ANY PERSON TO WHOM FORWARDING THIS COMMUNICATION IS PROHIBITED BY THE LEGENDS CONTAINED HEREIN. These materials are not
More information1H 2009/2010 Results Presentation
1H 2009/2010 Results Presentation 23 November 2009 1 1H 2009/10 Results Key Facts Consolidated Sales of 56,3m, -14.8% YoY Retail Sales of 14.7m, +118.3% YoY Wholesale Sales of 41.4m, -29.7% YoY EBITDA
More information9M2004 Consolidated Results
9M2004 Consolidated Results Fulvio Conti Chief Financial Officer Rome, 11 November 2004 Income statement (Euro Mn) 9M2004 9M2003 % change 3Q2004 3Q2003 % change 25,984 23,293 11.6% Revenues 9,036 7,872
More informationConference Call Q3-2015/2016 GEROLD LINZBACH, CEO I DIRK KALIEBE, CFO. February 10, 2016 ON THE RIGHT TRACK
Conference Call Q3-2015/2016 GEROLD LINZBACH, CEO I DIRK KALIEBE, CFO February 10, 2016 ON THE RIGHT TRACK On the right track Heidelberg is on track - the improvement in results due to the strategic realignment
More informationH1 2011 Strategy & Results Presentation. September 1 st, 2011
H1 2011 Strategy & Results Presentation September 1 st, 2011 1 Disclaimer This document has been prepared by ILIAD S.A. (the "Company ) and is being furnished to you personally solely for your information.
More informationInvestor & Analyst Presentation Acquisition of Centor US Holding Inc. Uwe Röhrhoff, CEO Rainer Beaujean, CFO Duesseldorf, July 28, 2015
Investor & Analyst Presentation Acquisition of Centor US Holding Inc. Uwe Röhrhoff, CEO Rainer Beaujean, CFO Duesseldorf, July 28, 2015 Disclaimer 1. This presentation may contain certain forward-looking
More informationFourth Quarter 2014. Published February 25, 2015. www.asetek.com
Fourth Quarter 2014 Published February 25, 2015 Disclaimer This presentation and its enclosures and appendices (jointly referred to as the Presentation ) has been produced by Asetek A/S (the Company )
More informationPREMIER OIL plc ("Premier") Result of Extraordinary General Meeting. 20th April 2009
Not for release, publication or distribution in or into Australia, Canada, the Dubai International Financial Centre, New Zealand, the Republic of South Africa, the State of Israel or the United States
More informationPRESS RELEASE 2015-12-15
PRESS RELEASE 2015-12-15 Balder acquires an additional 22.9 per cent of SATO mandates Carnegie and SEB to evaluate the possibility to implement a directed issue in order to partially finance the acquisition
More informationLocalised Cancer Treatment. PCI Biotech. Amphinex a new product for localised cancer treatment
Localised Cancer Treatment PCI Biotech Amphinex a new product for localised cancer treatment Disclaimer This document (the Presentation ) has been produced by PCI Biotech Holding ASA (the Company ). The
More informationFormation of Amlin Bermuda and rights issue to raise 215 million (net) November 2005
Formation of Amlin Bermuda and rights issue to raise 215 million (net) November 2005 Important notice This document, which is personal to the recipient and has been issued by Amlin (the Company ), comprises
More informationUbiquitous secure file sharing on any device
Ubiquitous secure file sharing on any device This presentation is not an offer to sell or a solicitation of an offer to purchase securities by Zyber Secure Mobile Solutions Inc. ( Zyber ). Any such offer
More informationB U I L D I N G N O R T H A M E R I C A N F I N T E C H L E A D E R S H I P. BMO 2013 Technology and Digital Media Conference
B U I L D I N G N O R T H A M E R I C A N F I N T E C H L E A D E R S H I P BMO 2013 Technology and Digital Media Conference Forward-Looking Statements This presentation contains certain statements that
More informationGjensidige Insurance Group Q4 2008 and preliminary 2008
Gjensidige Insurance Group Q4 2008 and preliminary 2008 Disclaimer The information contained herein has been prepared by and is the sole responsibility of Gjensidige Forsikring BA ( the Company ). Such
More informationNOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA.
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA. This press release is an advertisement and not a prospectus
More information